Combination of Daclatasvir, Asunaprevir, and Beclabuvir in treatment of Hepatitis C virus genotype 1
What is it about?
We assessed a combination of three drugs, namely Daclatasvir, asunaprevir, and beclabuvir, in treatment of Hepatitis C virus (HCV) genotype 1, which is the most prevalent HCV type globally and responsible for 60% of infection.
Why is it important?
This analysis showed high response rates in HCV genotype 1-infected patients treated with the combination irrespective of ribavirin use, prior interferon-based therapy, or restriction on non-cirrhotic patients, IL28B genotype, or baseline resistance-associated variants.
The following have contributed to this page: Mr Duy Hieu Truong and Mohamed Fahmy Doheim